This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
HOPE-3, or Heart Outcomes Prevention Evaluation-3, was a randomized phase 4 prevention trial in cardiovascular disease and stroke. The registry describes the study as a factorial trial with quadruple masking and 12,705 enrolled participants.
| Feature | HOPE-3 |
|---|---|
| Study title | Heart Outcomes Prevention Evaluation-3 |
| Phase | Phase 4 |
| Status | Completed |
| Conditions | Cardiovascular Disease; Stroke |
| Primary purpose | Prevention |
| Allocation | Randomized |
| Design model | Factorial |
| Masking | Quadruple |
| Enrollment | 12,705 |
| Number of arms | 2 |
| Lead sponsor | Population Health Research Institute |
| Sponsor type | OTHER |
| ClinicalTrials.gov | NCT00468923 |
2. Clinical Question
The registry identifies HOPE-3 as a prevention trial addressing cardiovascular disease and stroke. Its interventions were candesartan/HCT and rosuvastatin, within a randomized factorial design.
Population
Participants enrolled in a phase 4 prevention trial concerning cardiovascular disease and stroke.
Interventions
Candesartan/HCT and rosuvastatin.
Comparator structure
The registry identifies a randomized factorial design with 2 arms. The record summarized here does not provide further arm-level allocation details.
Primary question
How do the randomized interventions relate to the prespecified composite cardiovascular outcomes in a prevention setting?
3. Trial Design
The factorial designation is the central statistical feature of the design. In a factorial trial, interventions can be evaluated within a common randomized framework, allowing the study to address more than one intervention factor efficiently. The exact factor levels and allocation structure are not specified in the registry information summarized here, so the statistical interpretation should remain at the level of the documented factorial design rather than assuming an unreported treatment-cell structure.
4. Interventions and Randomized Structure
Candesartan/HCT
- Drug intervention.
- Evaluated within the randomized factorial design.
Rosuvastatin
- Drug intervention.
- Evaluated within the randomized factorial design.
5. Primary Endpoints
The registry lists two primary composite endpoints. Both use a time frame of biannually.
| Primary endpoint | Time frame | Statistical structure |
|---|---|---|
| The composite of; Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke. | Biannually | Composite clinical endpoint |
| The composite of; cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure, arterial revascularizations | Biannually | Composite clinical endpoint |
Why composite endpoints require careful interpretation
A composite endpoint combines several clinically distinct event types into a single statistical outcome. This can increase the number of observed events and may therefore provide greater statistical efficiency than analyzing a less frequent individual component alone.
At the same time, the components are not necessarily equally important clinically or equally frequent. A treatment effect on the composite therefore represents an effect on the combined endpoint, not automatically the same effect on every individual component.
For a conventional time-to-first-event composite, a participant enters the event analysis when the first qualifying component occurs. The precise event-counting and censoring conventions depend on the prespecified statistical analysis plan.
6. Statistical Methodology
Factorial analysis
The factorial design is intended to evaluate intervention factors within a shared randomized experiment. The main statistical advantage is efficiency: a participant can contribute information to the evaluation of more than one intervention factor rather than requiring a separate trial for each question.
A typical factorial analysis estimates the effect of each intervention factor while accounting for the factorial assignment structure. If the design permits it, investigators can also examine whether the effects of the intervention factors interact. Such an interaction asks whether the effect of one intervention differs according to the presence or absence of another intervention.
The interaction term is conceptually distinct from the two main effects. A factorial trial can estimate the main effects efficiently, while an interaction analysis asks whether the combined intervention effect differs from what would be expected from the separate effects.
Time-to-event analysis
Both registered primary endpoints are composite cardiovascular outcomes observed over time. For endpoints of this type, a standard analysis would generally use time-to-first-event methods such as Kaplan-Meier estimation and a Cox proportional-hazards model, with a corresponding comparison of event-time distributions between randomized groups.
These methods account for the fact that participants can have different lengths of observed follow-up and that some participants may reach the end of observation without experiencing a qualifying event.
Kaplan-Meier estimation
Here, di is the number of events at time ti and ni is the number of participants at risk immediately before that time.
Kaplan-Meier estimation is useful because it retains information from participants who remain event-free through their last observed follow-up. A survival curve for a composite cardiovascular endpoint would represent the probability of remaining free of any qualifying component of that composite over time.
Cox proportional-hazards model
A Cox model is commonly used to estimate a hazard ratio for a time-to-event endpoint. The hazard ratio compares the instantaneous event rates between groups under the model. It is a relative measure of event occurrence over the analyzed follow-up and is not equivalent to an absolute risk difference.
For a composite endpoint, the hazard ratio describes the relative rate of experiencing the first qualifying event from any component of the composite.
Log-rank comparison
A log-rank test is another standard method for comparing time-to-event distributions between randomized groups. It evaluates whether the observed pattern of event times differs between groups across follow-up, rather than comparing only a single fixed time point.
7. Planned Analysis
No formal statistical analyses were posted to ClinicalTrials.gov. The registry does, however, identify the two primary composite endpoints and their biannual time frame.
| Endpoint | What is measured | Typical statistical approach |
|---|---|---|
| Composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke | Occurrence of the first qualifying component over follow-up | Time-to-event analysis, commonly Kaplan-Meier estimation, log-rank comparison, and Cox modeling |
| Composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure, and arterial revascularizations | Occurrence of the first qualifying component over follow-up | Time-to-event analysis, commonly Kaplan-Meier estimation, log-rank comparison, and Cox modeling |
For the factorial structure, the primary statistical question would generally be framed around the main effects of the intervention factors, with an interaction term considered when the scientific question includes whether the effect of one intervention depends on the other.
The absence of posted statistical analyses means that the registry record establishes the endpoints and design but does not provide numerical hazard ratios, confidence intervals, event counts, or p-values for these endpoints.
8. Statistical Methods Explained
Why use a factorial design?
A factorial design allows more than one intervention factor to be studied within the same randomized trial framework. This can make efficient use of participants because information from the same study population can contribute to more than one intervention comparison.
What is the main statistical advantage of factorial randomization?
The key advantage is efficiency. Instead of requiring entirely separate randomized populations for each intervention question, a factorial structure can evaluate multiple intervention factors in a common experiment. The validity of the main-effect interpretation depends on the randomization and on assumptions about interaction between the factors.
What does an interaction mean in a factorial trial?
An interaction asks whether the effect of one intervention changes depending on the level of another intervention. For example, if the effect associated with one factor were materially different when the second factor was present than when it was absent, that would indicate effect modification by the second factor.
An important distinction is that a statistically significant main effect does not establish that there is no interaction. Main effects and interaction effects answer different questions.
Why use a composite cardiovascular endpoint?
A composite endpoint can increase the number of events available for analysis by counting several clinically relevant outcomes as a single endpoint. This can improve statistical efficiency when the components are scientifically coherent and occur often enough to contribute meaningful information.
The trade-off is interpretability. A composite result does not imply that every component changes to the same degree. Component-specific event patterns should therefore be considered whenever those data are available.
Why is time-to-event analysis appropriate?
Participants in a prevention trial may have different durations of observation. Some may experience a qualifying event, while others may remain event-free through the end of their observed follow-up. Time-to-event methods incorporate both the event indicator and the amount of observed time.
What does a hazard ratio actually measure?
A hazard ratio is a relative comparison of instantaneous event rates under a time-to-event model. An HR below 1 indicates a lower estimated hazard in one group relative to the reference group; an HR above 1 indicates a higher estimated hazard.
The hazard ratio is not an absolute probability and does not directly state how many fewer cardiovascular events occurred. Absolute risks at clinically meaningful time points provide a different and complementary description of treatment effect.
Why does a factorial trial need attention to multiplicity?
A factorial trial can involve several related statistical questions, including multiple intervention factors, more than one endpoint, and potentially an interaction. Testing many hypotheses increases the number of opportunities for a false-positive finding unless the confirmatory testing strategy is prespecified and appropriately controlled.
9. Interpreting the Two Primary Composite Endpoints
First composite
Combines cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. It focuses on three major cardiovascular outcomes.
Second composite
Expands the composite to include resuscitated cardiac arrest, heart failure, and arterial revascularizations in addition to cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
The two endpoints therefore represent different composite definitions. They should not be treated as interchangeable outcomes because the second composite includes additional event categories.
| Component | First primary composite | Second primary composite |
|---|---|---|
| Cardiovascular death | Included | Included |
| Non-fatal myocardial infarction | Included | Included |
| Non-fatal stroke | Included | Included |
| Resuscitated cardiac arrest | Not listed | Included |
| Heart failure | Not listed | Included |
| Arterial revascularizations | Not listed | Included |
10. Composite Endpoint Interpretation
A statistically estimated treatment effect on a composite endpoint would describe the relative occurrence of the combined endpoint as defined. It would not automatically establish an identical effect on cardiovascular death, myocardial infarction, stroke, heart failure, revascularization, or any other individual component.
If one component occurs much more frequently than the others, the overall composite estimate can be driven substantially by that component. Conversely, a rare but clinically important component can contribute relatively little to the statistical estimate despite its clinical importance.
Relative measures such as hazard ratios do not by themselves describe the underlying event burden. Absolute event probabilities or event counts are needed to understand the practical magnitude of an observed difference.
11. Factorial Design and Interaction
The factorial designation makes interaction an important statistical concept for HOPE-3. Suppose two intervention factors are represented by A and B. A conventional factorial model can distinguish the main effect of A, the main effect of B, and the interaction A×B.
| Model term | Question |
|---|---|
| Factor A | What is the effect associated with intervention factor A across the levels of factor B? |
| Factor B | What is the effect associated with intervention factor B across the levels of factor A? |
| A × B interaction | Does the effect of factor A differ according to the level of factor B? |
Interaction is especially important because an efficient factorial design generally relies on the assumption that the intervention factors can be evaluated within the same randomized framework without an interaction that materially changes the interpretation of the main effects.
12. Randomization and Causal Interpretation
Randomization is the central design feature supporting causal comparisons between assigned intervention groups. Because allocation is randomized, systematic differences in observed outcomes can be attributed to the randomized intervention under the assumptions of the trial design and analysis.
The factorial structure extends this logic to multiple intervention factors. Rather than interpreting the intervention names alone, the statistical analysis should follow the randomized assignment structure defined by the study.
Masking is listed as quadruple. This indicates that the registry classifies the trial as having four masked parties or roles, although the summarized record does not specify those roles individually.
13. Timing and Trial History
Study start
The registry lists May 2007 as the study start date.
Primary completion
The registry lists December 2015 as the primary completion date.
Registry status
The study status is listed as completed.
The time interval between study start and primary completion spans the period during which the randomized prevention study was conducted and its primary data collection was completed. The registry record summarized here does not provide event counts or numerical treatment-effect estimates.
14. Statistical Interpretation of Missing Numerical Results
For a randomized prevention trial with time-to-event composite endpoints, the numerical results needed to describe treatment effects would ordinarily include event counts, estimated event probabilities over time, a relative treatment-effect estimate such as a hazard ratio, a confidence interval, and a hypothesis-test result where applicable.
None of those numerical statistical results are posted in the ClinicalTrials.gov statistical-analysis fields represented here. Consequently, the documented evidence supports a detailed discussion of the trial design and endpoint structure, but not a numerical estimate of the intervention effects.
15. Limitations and Interpretation Issues
- No posted statistical estimates: The ClinicalTrials.gov record represented here does not contain formal statistical analyses for the registered primary endpoints, so hazard ratios, confidence intervals, p-values, and numerical event rates cannot be described from the registry record.
- Factorial structure: The registry identifies the study as factorial but the summarized record does not provide the complete factorial cell structure. Interpretation should therefore avoid assuming unreported treatment combinations or allocation counts.
- Composite endpoints: Each primary endpoint combines multiple clinical events. A composite effect is not necessarily an effect of identical magnitude on each component.
- Different endpoint definitions: The two primary composites contain different sets of events and therefore answer different statistical questions.
- Multiplicity: Two primary endpoints and a factorial design can create multiple related statistical questions. Formal interpretation depends on the prespecified multiplicity strategy.
- Interaction: A factorial design raises the possibility that one intervention's effect depends on another intervention. Main effects and interaction effects should be interpreted separately.
- Time-to-event assumptions: A Cox-model analysis, if used, relies on assumptions concerning the hazard structure. A single hazard ratio can be less informative when hazards are substantially non-proportional.
- Censoring: Time-to-event methods depend on appropriate handling of participants who do not experience a qualifying event during observed follow-up.
- Endpoint components: The relative frequency and clinical importance of individual components can affect how a composite result should be understood.
16. Why This Trial Matters Statistically
HOPE-3 provides a useful teaching example because its registry design combines randomized allocation, factorial structure, quadruple masking, prevention, and two composite cardiovascular endpoints.
| Concept | How it appears in HOPE-3 |
|---|---|
| Randomization | The registry identifies randomized allocation. |
| Factorial design | The registry identifies a factorial design model involving candesartan/HCT and rosuvastatin. |
| Masking | The registry lists quadruple masking. |
| Prevention | The primary purpose is listed as prevention. |
| Composite endpoints | Both registered primary endpoints combine multiple cardiovascular events. |
| Time-to-event analysis | The endpoints are clinical event composites assessed over time, making time-to-event methods a natural analytical framework. |
| Interaction | The factorial design makes assessment of potential intervention interaction an important statistical concept. |
| Multiplicity | Multiple primary endpoints and factorial intervention questions require a prespecified inferential strategy. |
| Censoring | Time-to-event analyses must account for participants who remain event-free through their observed follow-up. |
| Absolute versus relative effects | Hazard ratios and absolute event probabilities answer different statistical questions. |
17. Related Statistical Concepts
Learn more about the methods used in this trial:
18. Related Statistical Calculators
19. Sources
- ClinicalTrials.gov: NCT00468923.
Continue through the Clinical Biostats knowledge graph
Explore statistical tutorials and calculators that explain clinical-trial design, composite endpoints, and factorial analysis.
20. Record Summary
HOPE-3 is a completed randomized phase 4 prevention trial involving 12,705 participants and a factorial design evaluating candesartan/HCT and rosuvastatin in the setting of cardiovascular disease and stroke. Its two registered primary endpoints are composite cardiovascular outcomes assessed on a biannual time frame. The statistical structure is particularly useful for understanding how factorial randomization, composite endpoints, time-to-event analysis, interaction, censoring, and multiplicity fit together.
The most important statistical distinction is between the design of the trial and the numerical results of the trial. The ClinicalTrials.gov record establishes the randomized factorial design and the prespecified composite endpoints, but the statistical-analysis fields represented here do not contain numerical treatment-effect estimates. That makes the design and planned analytical framework the central statistical features of this record.